CCS1477
50+
Epigenetic-related targets
investigated over time by the CellCentric team
1
Drug prioritised, advanced
CCS1477 in the clinic, to treat specific cancers
The target
p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.
CCS1477 is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.
CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.
Another clinical site open: Simon Pacey and the CCTC team, Cambridge. p300/CBP inhibitor CCS1477 to treat targeted tumours & prostate cancer. pic.twitter.com/2rPQmqNdAV
Evaluating CCS1477 to treat haematological malignancies, another site open. First in class p300/CBP inhibitor to treat multiple myeloma, AML, lymphomas. pic.twitter.com/SUrVRfswUy
Our latest blog on our recent CCS1477 publication in Cancer Discovery. Lab to patients, a massive team effort. cellcentric.com/updates/blog-n… pic.twitter.com/tXvnfX9fg8